CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial

ConferenceIn vivo CAR cell therapyPositive

AI Analysis

Summary

CellOrigin announced two novel solid-tumor cell therapy candidates at ASCO 2026 and established a partnership with Walvax for an in vivo CAR clinical trial. The announcement represents progress in the company's cell therapy development pipeline.

Clinical Trial Data

Importance:6/10

Sentiment:

0.60

cell therapysolid tumorsin vivo CARASCO 2026partnershipclinical trial

Related Companies

$GBIO $HGZDY $SLDB $CHHE

Read the original article

Published by PR Newswire Pharma on July 31, 2026 6:15 AM

Read Original